<

EPIGENOMICS AG (FRA:ECX) EQS-Adhoc: Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024

Transparency directive : regulatory news

30/10/2023 15:49

EQS-Ad-hoc: Epigenomics AG / Key word(s): Personnel
Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024

30-Oct-2023 / 15:49 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024

Berlin, Germany, October 30, 2023 – Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX1, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024, due to the successful transfer of nearly all assets of the Company to New Day Diagnostics LLC. The Supervisory Board will appoint a new Executive Board member in due course and decide on the further composition of the Executive Board.

 

Contact:
Company
Epigenomics AG, Bertha-Benz-Strasse 5, 10557 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com


Note on forward-looking statements

This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.

 



End of Inside Information

30-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Epigenomics AG
Bertha-Benz-Straße 5
10557 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A32VN83
WKN: A32VN8
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1760753

 
End of Announcement EQS News Service

1760753  30-Oct-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1760753&application_name=news&site_id=symex


Other stories

28/04/2024 12:53
28/04/2024 13:47
28/04/2024 14:10
28/04/2024 11:13
28/04/2024 08:19
28/04/2024 13:03
28/04/2024 14:30
28/04/2024 11:09
28/04/2024 09:00
28/04/2024 12:48
28/04/2024 09:23
27/04/2024 22:24
28/04/2024 10:15
27/04/2024 23:54
28/04/2024 11:57
27/04/2024 18:51
28/04/2024 14:00
27/04/2024 21:00
28/04/2024 09:00
28/04/2024 08:49
27/04/2024 19:51
28/04/2024 13:53
28/04/2024 01:52
28/04/2024 08:53
28/04/2024 11:24
28/04/2024 12:20
28/04/2024 14:12
28/04/2024 14:04
28/04/2024 13:17
28/04/2024 12:39
27/04/2024 14:00
28/04/2024 09:42
27/04/2024 20:48
28/04/2024 11:41
27/04/2024 13:26
28/04/2024 03:31
28/04/2024 09:00
27/04/2024 10:19